Reference health
Seroprevalence to SARS-CoV-2 in Patients with Rheumatic Diseases on Disease Modifying Antirheumatic Drugs and /or Immunosuppressive Medications from India: A Multicentric Study
20/20 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 20 checked references that resolve
resolves10.1001/jama.2020.6775
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
resolves10.1136/annrheumdis-2020-219498
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1136/annrheumdis-2021-eular.594
POS0048 SEROPREVALENCE OF ANTI-SARS-COV-2 ANTIBODIES IN RHEUMATIC PATIENTS TREATED WITH BIOLOGICAL AND TARGETED THERAPY LIVING IN LOMBARDY, ITALY (MAINSTREAM PROJECT)
resolves10.1016/S2214-109X(20)30544-1
SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
resolves10.1017/S0950268821000972
Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys
resolves10.1007/s15010-021-01651-4
IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
resolves10.1007/s10096-021-04284-5
Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
resolves10.1073/pnas.2021615118
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
resolves10.1186/s13075-020-02395-6
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
resolves10.1007/s11739-020-02535-5
Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
resolves10.1016/S2665-9913(21)00151-X
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
resolves10.1007/s10067-021-05779-4
Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
resolves10.1001/jamainternmed.2021.0366
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
resolves10.1007/s10067-021-05801-9
Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
resolves10.1016/S2665-9913(21)00037-0
Perspective of patients with autoimmune diseases on COVID-19 vaccination
resolves10.1136/annrheumdis-2021-220272
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
The 9 references without a DOI — listed, not checked
no DOI — not checkedref1
no DOI — not checkedref2
no DOI — not checkedSeroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases
no DOI — not checkedSerum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection
no DOI — not checkedSARS-CoV-2 seroprevalence among the general population and healthcare workers in India
no DOI — not checkedChemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population
no DOI — not checkedCOVID-19 and Disease-Modifying Anti-rheumatic Drugs
no DOI — not checkedPrevalence and clinical outcomes of COVID19 in patients with autoimmune diseases: a systematic review and meta-analysis
no DOI — not checkedCOVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4011276"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4011276/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4011276)